RESUMO
The severe side-effects elicited by conventional antibiotic therapy and the recurrence of Bacterial vaginosis-associated bacteria and bacterial resistance have led to the development of novel alternative therapies, among which genital probiotics are widely used. In this study, we aimed to evaluate the antimicrobial activities of Lactobacillus plantarum Lp62 and its supernatant against Gardnerella vaginalis, using both in vitro and in vivo approaches. In vitro assays were used to evaluate the viability of the strain and the antimicrobial activities of the supernatant in different pH ranges. An in vivo assay was performed on female BALB/c mice, wherein the animals were divided into eight groups: four control groups and four treated groups (for curative and preventive therapies). After infecting and treating the mice, the animals were killed to quantify the bacterial load using qPCR, evaluate leucocyte cellular response, determine vaginal cytokine levels and perform cytokine tissue gene expression. Our analyses revealed significant activity of the strain and its supernatant against G. vaginalis. Preliminary in vitro tests showed that the strain grew with equal efficiency in different pH ranges. Meanwhile, the presence of halo and inhibition of pathogen growth established the significant activity of the supernatant against G. vaginalis. We observed that both micro-organisms are resident bacteria of mouse microbiota and that the lactobacilli population growth was affected by G. vaginalis and vice versa. We also observed that the treated groups, with their low bacterial load, absence of leucocyte recruitment, reduced cytokine levels in the vaginal lavage and normalized cytokine gene expression, successfully controlled the infection.
Assuntos
Lactobacillus plantarum , Probióticos , Vaginose Bacteriana , Animais , Feminino , Gardnerella vaginalis , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Vaginose Bacteriana/terapiaRESUMO
This in vitro study evaluated the antimicrobial activity of extracts obtained from Rheedia brasiliensis fruit (bacupari) and its bioactive compound against Streptococcus mutans. Hexane, ethyl-acetate and ethanolic extracts obtained (concentrations ranging from 6.25 to 800 microg/ml) were tested against S. mutans UA159 through MIC/MBC assays. S. mutans 5-days-old biofilms were treated with the active extracts (100 x MIC) for 0, 1, 2, 3 and 4h (time-kill) and plated for colony counting (CFU/ml). Active extracts were submitted to exploratory chemical analyses so as to isolate and identify the bioactive compound using spectroscopic methods. The bioactive compound (concentrations ranging from 0.625 to 80 microg/ml) was then tested through MIC/MBC assays. Peel and seed hexane extracts showed antimicrobial activity against planktonic cells at low concentrations and were thus selected for the time kill test. These hexane extracts reduced S. mutans biofilm viability after 4h, certifying of the bioactive compound presence. The bioactive compound identified was the polyprenylated benzophenone 7-epiclusianone, which showed a good antimicrobial activity at low concentrations (MIC: 1.25-2.5 microg/ml; MBC: 10-20 microg/ml). The results indicated that 7-epiclusianone may be used as a new agent to control S. mutans biofilms; however, more studies are needed to further elucidate the mechanisms of action and the anticariogenic potential of such compound found in R. brasiliensis.
Assuntos
Benzofenonas/farmacologia , Benzoquinonas/farmacologia , Clusiaceae/química , Extratos Vegetais/farmacologia , Streptococcus mutans/efeitos dos fármacos , Biofilmes , Testes de Sensibilidade MicrobianaRESUMO
The present study evaluated the chemical composition and the antimicrobial activity of the extracts and fractions of Mikania laevigata and Mikania glomerata on growth and cell adherence of mutans streptococci. Ethanolic extract, hexane and ethyl acetate fractions of Mikania laevigata and Mikania glomerata were chemically identified by chromatographic methods and tested on mutans streptococci from culture collection and clinical isolates. Twenty-two compounds were identified in both Mikania extracts, including coumarin, 1-octadecene, and diterpenic, cupressenic and kaurenoic acids. Antimicrobial activity was assessed by determination of the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and inhibition of cell adherence to a glass surface. Hexane fraction from both plant extracts was the most effective in inhibiting the growth of the bacterial strains tested (MIC values between 12.5 microg/ml and 400 microg/ml, and MBC values between 25 microg/ml and 400 microg/ml). In addition, sub-MIC levels of the crude extracts and their hexane fractions significantly inhibited the adherence of the microorganisms to a glass surface. The data indicate that the biologically active compounds are present mostly in the hexane fraction of both Mikania species, which showed remarkable inhibitory activities against mutans streptococci. Mikania genus plant is a promising source for novel antimicrobial agents against oral pathogens.
Assuntos
Antibacterianos/isolamento & purificação , Mikania , Extratos Vegetais/isolamento & purificação , Plantas Medicinais , Streptococcus mutans/efeitos dos fármacos , Antibacterianos/química , Antibacterianos/farmacologia , Aderência Bacteriana/efeitos dos fármacos , Cromatografia Gasosa-Espectrometria de Massas , Testes de Sensibilidade Microbiana , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Streptococcus mutans/crescimento & desenvolvimento , Streptococcus mutans/metabolismoRESUMO
The effects of a new variety of propolis, from Northeastern Brazil (BA), on growth of mutans streptococci, cell adherence, and water-insoluble glucan (WIG) synthesis were evaluated. Propolis from Southeastern (MG) and Southern (RS) Brazil were also tested as an extension of our previous work. Ethanolic extracts of propolis (EEP) were prepared and analyzed by reversed-phase HPLC. For the antibacterial activity assays, minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) of EEPs against Streptococcus mutans, S. sobrinus, and S. cricetus were determined. Cell adherence of S. mutans and S. sobrinus to a glass surface was measured spectrophotometrically at 550 nm. WIG synthesized from sucrose by glucosyltransferase (Gtf) was extracted and quantified by the phenol-sulfuric method. The HPLC profile of the new variety of propolis was entirely different from Southeastern and Southern propolis. Neither flavonoid aglycones nor p-coumaric acid were detected in EEP BA. All EEPs demonstrated biological activities against mutans streptococci; EEP BA showed the highest potency in all in vitro parameters evaluated in this study. The ranges of MIC values were 50 (EEP BA)-400 microg/ml (MG), for S. mutans; and 25 (BA)-400 microg/ml (MG), for S. sobrinus and S. cricetus. The bactericidal concentration of EEPs was four to eight times the MIC values. The adherence of S. mutans and S. sobrinus cells and WIG synthesis were markedly inhibited by EEPs, demonstrating significant inhibition at all concentrations compared with the control (80% ethanol) (p<0.05). EEP BA showed 80% inhibition of cell adherence and WIG synthesis at concentrations as low as 12.5 and 7.8 microg/ml, respectively. The results show that the new variety of propolis was exceptionally effective in all in vitro parameters tested against mutans streptococci; biological effects of propolis are likely not to be due solely to flavonoids and (hydroxy)cinnamic acid derivatives.
Assuntos
Abelhas , Própole/farmacologia , Streptococcus mutans/efeitos dos fármacos , Animais , Aderência Bacteriana/efeitos dos fármacos , Cromatografia Líquida de Alta Pressão , Glucanos/análise , Glucanos/biossíntese , Glucosiltransferases/antagonistas & inibidores , Glucosiltransferases/metabolismo , Espectrofotometria , Streptococcus mutans/metabolismo , Sacarose/metabolismoRESUMO
The use of propranolol is generally contraindicated in patients with congestive heart failure. However, we successfully used a continuous high-dose infusion of propranolol, in combination with the use of extracorporeal life support (ECLS) and intra-aortic balloon pumping (IABP), to treat refractory life-threatening ventricular tachycardia in a patient with postoperative congestive heart failure. The early combined use of ECLS and IABP before irreversible myocardial damage contributed to the successful outcome.